AI-Driven CDMO Solutions for Advanced Protein Expression and Antibody Drug Development

The demand for high-quality recombinant proteins and antibody-drug conjugates (ADCs) continues to grow, yet the development pipeline remains challenged by long timelines, high failure rates, and escalating costs. Creative BioMart's AI-driven CDMO platform addresses these bottlenecks head-on by seamlessly integrating artificial intelligence with experimental biology.

In this webinar, Dr. Zhu will introduce Creative BioMart's integrated AI platform, which enables accurate 3D structure prediction, affinity maturation, immunogenicity risk assessment, and de novo antibody design — significantly reducing development time and cost. The session will cover our GMP-compliant facilities, scalable mammalian and microbial expression systems, and comprehensive quality control processes. Attendees will learn how our AI-first, dry-wet closed-loop approach achieves high success rates in antibody engineering and membrane protein production, supporting next-generation biotherapeutics.

More information